search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Women’s health


the evidence base underpinning their care may not fully reflect them. Treatments for cardiovascular disease, type 2 diabetes, and obesity have historically been developed and validated in study populations where women were underrepresented. As a result, the need to participate in


research is not always apparent. Clinical studies are often presented as opportunities to access new therapies, rather than as a means of addressing gaps in evidence that directly affect patient outcomes. If the evidence base does not adequately reflect you, the personal relevance of participation may be much less apparent. This creates a disconnect. Individuals are being asked to participate in research without a clear understanding of why their participation matters, not just for science, but for the quality of care they themselves may receive. From a behavioural perspective, participation


is more likely when individuals perceive a direct and meaningful benefit.8


recruitment efforts rely heavily on external prompts rather than intrinsic motivation. This has been observed in cardiometabolic


prevention and risk-based studies, where proactive identification through community screening programmes has increased participation, particularly among women.6


Without that connection,


a question of fairness or generalisability. It becomes a structural issue that shapes how future evidence is generated and applied. Improving representation at the point of data generation is therefore critical, not only for today’s studies, but for the integrity of the systems that will increasingly guide clinical research and care.


Conclusion The persistent under-representation of women in cardiometabolic studies is often framed as a recruitment challenge. But the evidence suggests something more fundamental. Women are not absent from research because they are unwilling to participate. They are underrepresented because the way research is delivered is not designed around the realities of their lives. Studies continue to rely on episodic, site-based


By


linking research opportunities to existing health concerns — such as weight management, diabetes risk or cardiovascular prevention — these approaches increase personal relevance and shift participation from opportunistic to intentional.8,10


Therefore, under-representation


is not only a question of who can participate, but who sees a reason to.


The emerging risk: bias at scale As clinical research becomes increasingly data- driven, the implications of under-representation extend beyond individual studies. Artificial intelligence and advanced analytics are playing a growing role in study design, patient identification, and clinical decision-making. These systems are often trained on historical datasets derived from existing clinical research and healthcare records. If those datasets under-represent women, the risk is not only that gaps persist, but that they are amplified. Bias is no longer just a historical artefact; it becomes a scalable feature of the system. Algorithmic models may inadvertently learn patterns that reflect historical biases in diagnosis, treatment pathways, and outcomes. This can influence everything from eligibility criteria and site selection to how risk is assessed and interventions are prioritised. Under-representation is no longer just


recruitment models that assume availability, flexibility, and proximity to clinical settings. These assumptions do not hold for many women, particularly those balancing caregiving responsibilities, employment, and long-term health management. The result is not simply slower recruitment, but systematic exclusion. As clinical research becomes more dependent on data-driven and AI-enabled approaches, the consequences of this exclusion extend further. Bias in participation risks becoming bias in evidence, and ultimately bias in care. What emerges from the literature is a


consistent signal: representation improves when research is brought closer to communities, when engagement occurs in outpatient or typical settings, and when participants have an existing relationship with the healthcare environment before a study begins. This points to a broader conclusion: improving


representation is not primarily about refining recruitment tactics. It requires a shift in infrastructure, from study-centric recruitment to continuous engagement with populations through the healthcare environments they already use and trust. Approaches that build longitudinal relationships with individuals, support ongoing interaction with their health, and embed research into everyday care pathways offer a more viable route to inclusive participation. Representation is not a recruitment outcome; it is a design choice. And until clinical research is designed around the realities of the populations it seeks to serve, under-representation will persist, not because women are hard to reach, but because the system has not been built to include them. CSJ


References 1. Vogel B, et al. The Lancet Commission on women


54 www.clinicalservicesjournal.com I November 2026 and cardiovascular disease. The Lancet, 2021


2. Burgess S, et al. Under-representation of women in cardiovascular trials. Am Heart J, 2024


3. Spiering AE, et al. Under-representation of women in cardiovascular disease trials. Eur J Prev Cardiol, 2024


4. Unger JM, et al. Barriers to clinical trial participation. Journal of the National Cancer Institute, 2019


5. Van Spall HGC, et al. Eligibility criteria of randomized trials. Journal of the American Medical Association, 2007


6. Scott PE, et al. Participation of women in cardiovascular trials. Journal of the American College of Cardiology, 2018


7. Liu KA, Mager NA. Women’s involvement in clinical trials. Pharm Pract, 2016


8. Staley K. Transforming patient engagement in clinical trials. Drug Discovery Today, 2023


9. Designing inclusive clinical trials: how researchers can drive change to improve diversity, BMJ 2025; 388:e082486


10. Glasgow RE, et al. RE-AIM framework / implementation science, Preventive engagement / participation models


About the author


Mark Campbell is CEO of Civia Health, where he has spearheaded the development of a new model for clinical research. By combining study- ready participant populations with dedicated operational capacity, the model is designed to give sponsors greater enrolment certainty, faster study delivery and lower operational risk creating the infrastructure to generate valid evidence at scale while improving the human experience of clinical research. Mark previously co-founded EmVenio


Research, where he led the expansion of community-based trial sites to improve access to clinical research for underrepresented populations. He also led global service delivery at Synexus (PPD AES) and began his career at Johnson & Johnson and Amgen.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71